This is the authors' abstract. We don't add key points for this paper.
This article reviews the existing data in an attempt to address the role of biological response modifiers (IFN-alpha and IL-2) in the management of melanoma. Eight prospective controlled Phase III trials evaluating IFN-alpha therapy are discussed. As the results from these trials have been heterogeneous and inconsistent, the role of IFN-alpha in the adjuvant treatment of stage II and III melanoma patients remains to be defined. IL-2 possesses modest antitumour activity in melanoma yielding objective response in approximately 15% of patients. Many toxic effects are induced by high-dose IL-2 therapy. Combinations of chemotherapy and biological response modifiers and their impact on tumour response and survival are discussed.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Marko Lens (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: